Skip to content

Genetic and Epigenetic Variations in Heterokaryotypic Monozygotic Twins Discordant for Down Syndrome

Genetic and Epigenetic Variations in Heterokaryotypic Monozygotic Twins Discordant for Down Syndrome

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05767216
Acronym
Colibri
Enrollment
5
Registered
2023-03-14
Start date
2022-12-20
Completion date
2028-12-30
Last updated
2023-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Down Syndrome

Brief summary

Heterokaryotypic monozygotic twins discordant for Down syndrome (DS) are very rare, with an incidence estimated to be less than 1 over 7,000,000 pregnancy in the general population. Sharing the same genetic patrimony, except for an additional chromosome 21 for one of them, any gene-expression difference between them could be attributed only to the supernumerary chromosome 21 and not to polymorphic variability in the rest of the genome. The setting up of a prospective longitudinal study will offer the major advantage of allowing genetic and epigenetic comparisons between them and to obtain important information on the impact of the environment in which they live and grow up.

Detailed description

It is planned to perform multi-omics analyses in order to reach an integrated understanding of the effect of genomic changes on protein expression, on biochemical posttranslational modifications of the synthetized proteins and on the modulation of some signalling pathways. This study will also allow the generation of induced Pluripotent Stem Cells (iPSCs) from blood cells and fibroblasts of the monozygotic twins useful as in-vitro models to study the pathogenesis and the pathophysiology of Down syndrome. All this may shed the light on new research approaches in Down syndrome. At last, the human gut microbiome, referring to the total microbial population in the human gastrointestinal tract, although thought to have its own impact, will also be studied. The microbiome is known to play a crucial role mainly in protecting the host against pathogenic microbes, modulating immunity, regulating metabolic processes, and controlling neuropsychiatric behaviour

Interventions

OTHERBiological sampling

Blood, skin and stool samples for laboratory analysis

Sponsors

Institut Jerome Lejeune
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
4 Years to 11 Years
Healthy volunteers
Yes

Inclusion criteria

* Twins of a heterokaryotypic monozygotic pair discordant for DS * Twins of a sex- and class of age-matched dizygotic pair discordant for DS, * Sex- and class of age-matched patient with mosaic T21 * Subject's parents/legal representatives willing to give written informed consent. * Subject and his/her parents/legal representatives must be able/willing to comply with the protocol. * Subject covered by social welfare.

Exclusion criteria

* None

Design outcomes

Primary

MeasureTime frameDescription
Analysis of the coding and non-coding genetic variations between participants1 yearWhole Genome Sequencing of DNA samples
Study of epigenetic modifications1 yearDNA methylation pattern
Identification of active genes1 yearAnalysis of transcriptomic profile from RNA samples
Determination of the mechanisms of genes regulation1 yearAnalysis of transcriptomic profile from RNA samples
Definition of the network of genes expression1 yearAnalysis of transcriptomic profile from RNA samples
Identification of the proteins regulated differently1 yearAnalysis of proteomic profile from plasma samples
Link specific proteins to some specific complications seen in patients with Down syndrome1 yearAnalysis of proteomic profile from plasma samples

Countries

France

Contacts

Primary ContactSophie Durand
sophie.durand@institutlejeune.org0033156586300

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026